Skin Cancer & Melanoma

Preclinical analyses have indicated that microRNA-18b may have a role as a tumor suppressor, has the potential to be a biomarker for melanoma, and its overexpression may be a novel therapeutic strategy for the treatment of melanoma.

The overall diagnostic accuracy of smart phone applications designed to help nonclinicians identify malignant skin lesions was highly variable, with three of four of the applications wrongly classifying 30% of melanomas.

The anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody tremelimumab failed to achieve a significant improvement in survival among patients with metastatic melanoma compared with the standard of care treatments used in the comparator arm, according to the results of a phase III study.

Researchers using a mouse model of melanoma were able to prevent resistance to vemurafenib by altering the dosing schedule from a continuous daily dose to an intermittent dose.

No improvement in overall survival was seen in patients with metastatic melanoma who were assigned treatment with sorafenib in combination with carboplatin/paclitaxel for the treatment of their disease, according to the results of a double-blind, phase III study.

In this podcast we discuss the recent advances in the management and treatment of metastatic melanoma with Jeffrey Sosman, MD, medical oncologist and director of the Melanoma and Tumor Immunotherapy Program at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

In this interview, Dr. Mario Sznol shares unique insights into two treatment approaches for melanoma--targeted therapies and a drug that targets the Programmed Death 1 pathway-including how they compare and how they might be combined.

We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit–activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec).

A new review of the literature shows that melanoma is substantially more common in immunosuppressed patients, including those with prior solid organ transplant and individuals with lymphoma.

Phase II results presented at the ESMO 2012 Congress showed a 3.6-month improvement in progression-free survival for patients receiving both dabrafenib plus trametinib compared to those receiving dabrafenib alone.

Patients with node-negative melanoma undergoing sentinel lymph node excision who were given preoperative imaging with SPECT/CT experienced a higher frequency of metastatic involvement and a longer disease-free survival compared to those without preoperative SPECT/CT.

A new epigenetic hallmark of melanoma has been identified, which has a critical function in disease development, and may serve as a potential target for reversing melanoma progression.

The oral selective MEK inhibitor trametinib improved progression-free and overall survival over chemotherapy in patients with metastatic melanoma with a BRAF mutation, according to a new phase III trial.

Sentinel lymph node biopsy is recommended for patients with newly diagnosed intermediate-thickness melanomas, while the procedure may not be indicated for patients with thinner lesions, according to a new set of guidelines.

A new target of melanoma tumors has been identified that may be promising as part of a novel combination therapy for melanoma. In a study published in Nature Medicine, researchers have identified that more than half of melanoma cases, both early and late-stage, may have higher levels of MDM4, a p53-interacting protein.

A new study finds cutaneous human papillomavirus infection can increase the risk of squamous-cell carcinoma, a nonmelanoma skin cancer.

In a phase III trial, the oral BRAF inhibitor dabrafenib, improved progression-free survival in previously untreated metastatic melanoma patients.

At the ASCO annual meeting, researchers presented persuasive evidence that a new class of targeted agents-MEK inhibitors-may warrant inclusion in the growing armamentarium for patients with advanced BRAF-mutated melanoma.

In this exclusive interview, Michael B. Atkins, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses some of the most important melanoma research to come out of this year’s ASCO meeting and talks about the future of melanoma therapies.

Data from the phase III BREAK-3 and the phase II BREAK-MB trials of dabrafenib establish the drug as the second BRAF inhibitor for BRAF V600E-mutated melanoma.

The class of agents that target the Programmed Death 1 (PD-1) pathway was described at ASCO as “likely the most exciting new agents recently developed in melanoma.”

The new therapies that became available for advanced melanoma over the past year-the anti-CTLA4 antibody ipilimumab (Yervoy) and the selective BRAF inhibitor vemurafenib (Zelboraf)-represent promising new options for these patients, whose prognosis was heretofore almost universally dismal. However, the advent of new treatment strategies has made treatment decisions more complex.

Researchers have shown that patients who use nonsteroidal anti-inflammatory drugs like aspirin and ibuprofen are less likely to develop three types of skin cancer.

A new analysis of four large European trials of cutaneous melanoma patients showed a substantial survival advantage for women, most likely explained by underlying biologic differences.

The addition of sorafenib to isolated limb infusion therapy with melphalan did not improve responses in a new phase I trial of patients with in-transit extremity melanoma.